Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.

A blood-based microRNA assay combined with carbohydrate antigen 19-9 detects early-stage pancreatic ductal adenocarcinoma with 86.8% sensitivity in a large international study.

• Why it matters: Early detection of pancreatic ductal adenocarcinoma (PDAC) remains a major challenge, limiting treatment options and survival rates; a minimally invasive blood test could significantly improve outcomes.
• What they did: Researchers developed and validated a microRNA signature and a composite score, PANXEON, in a prospective study involving 1,785 individuals across four countries, assessing its ability to detect early-stage PDAC.
• The result: The assay achieved high sensitivity and specificity, showing promise for early diagnosis, monitoring treatment response, and identifying high-grade dysplasia, supporting further large-scale validation.